• Numinus Wellness (NUMI) has completed the acquisition of Novamind Inc.
  • Numinus now operates 13 wellness clinics, four clinical research facilities and a dedicated psychedelics research lab
  • Numinus Founder and CEO Payton Nyquvest sat down with Coreena Robertson to discuss the news
  • Numinus also announced the appointments of Dr. Reid Robison as Chief Clinical Officer and Dr. Paul Thielking as Chief Science Officer
  • Numinus Wellness Inc. (NUMI) opened trading at C$0.365

Numinus Wellness (NUMI) has completed the acquisition of Novamind Inc. following shareholder and court approvals

Numinus now operates 13 wellness clinics, four clinical research facilities and a dedicated psychedelics research lab – positioning the company as a leading integrated mental wellness company providing ketamine- and psychedelic-assisted therapies. 

Numinus Founder and CEO Payton Nyquvest sat down with Coreena Robertson to discuss the news.

“This acquisition elevates our collective service offering, and we look forward to helping an even greater number of people access effective and safe treatments to support mental wellness. We warmly welcome the Novamind team to Numinus and believe our shared values and focus on client service will ensure a seamless integration as we continue to grow as one unified company.”

Numinus also announced the appointments of Dr. Reid Robison (MD) as Chief Clinical Officer and Dr. Paul Thielking (MD) as Chief Science Officer, both from Novamind.

Numinus Wellness Inc. is a mental health and wellness company.

Numius Wellness Inc. (NUMI) opened trading at C$0.365.

More From The Market Online

@ the Bell: U.S. Fed to hold interest rates steady

The U.S. Federal Reserve keeps its key interest rate unchanged at roughly 5.3 per cent on Wednesday while Canada’s main stock index rises.

Sonoro Energy’s smart acquisition in the MENA region

Sonoro Energy recently announced a significant Middle East-North Africa (MENA) region play that could reshape its operational landscape.

Optimi Health completes first MDMA shipment to Israel

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.